Prolgolimab (BCD-100) is a fully human monoclonal antibody that has specific affinity for the PD-1 receptor. It is an IgG1 immunoglobulin with L234A/L235A mutations which result in lower affinity to Fcγ receptors. It is the first immune checkpoint inhibitor developed in Eastern Europe.

Prolgolimab is already approved in Russia for the treatment of unresectable or metastatic melanoma. As part of the Harmony clinical program, prolgolimab is also being developed in combination with other therapies for the treatment of advanced NSCLC and cervical cancer.